Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 31

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 31
---
 1 Kadimastem Ordinary Share. (vii) Transfer restrictions regarding the new registered shares: none. (viii) Restriction or cancellation of subscription rights and the consequences of subscription rights not exercised or withdrawn: The subscription rights of all shareholders in respect of this capital increase are cancelled because the new shares will be used for the settlement of the acquisition of all shares in Kadimastem under the Merger Agreement and the newly issued NLS Common Shares will be allocated to the (then former) shareholders of Kadimastem. The figures set above are not final numbers and may be adjusted once the reverse split ratio and Exchange Ratio are finalized. The decision on the reverse split ratio will be taken based on the market price of the NLS Common Shares immediately prior to the NLS Meeting. The reverse split ratio will be within a range of two -for -one(2:1) to twenty -for -one(20:1). The final Exchange Ratio will be determined pursuant to a formula and in accordance with the terms of the Merger Agreement. The final Exchange Ratio is subject to certain adjustments, including as a result of estimated cash of NLS and Kadimastem and estimated indebtedness of NLS, in each case as measured at the close of business on the day preceding the NLS Meeting. The number of new registered NLS Common Shares to be issued to Kadimastem shareholders will be between 30,000,000 and 70,000,000shares (before applying the reverse split ratio). The reverse split ratio has an impact on the possible par value reduction and as a result on the cash capital increase required to allow the reverse split ratio. The cash capital increase is expected to be less than CHF 1.00 in total. Since the nominal registered capital after the Closing needs to be

at least as high as the nominal registered capital in place before this NLS Meeting resolution takes effect, NLS would use shares issued to the Kadimastem shareholders as Merger consideration. Therefore, the final split ratio of the Merger has an indirect impact on the par value reduction. The figures set above will be decided no later than the morning of the NLS Meeting. This does not constitute an amendment to the proposal given that this has no economic impact on the shareholders. 3.Ordinary Share Capital Increase by Issuing Preferred Shares Explanation:The Company entered into a securities purchase agreement dated December 4, 2024 (the “ PIPE SPA”), with a certain accredited investor. Pursuant to